Research Paper Volume 13, Issue 4 pp 5150—5163

Nampt promotes osteogenic differentiation and lipopolysaccharide-induced interleukin-6 secretion in osteoblastic MC3T3-E1 cells

FK866, a Nampt inhibitor, inhibited IL-6 induced inflammation and osteogenic differentiation. After treatment with 1 nM FK866 and 100 ng/mL LPS for 3 days, (A) NAD+/NADH analysis showing intracellular content of NAD+ and NADH, and their ratio. (B) ELISA result showing the IL-6 levels. (E) The nuclear translocation of NF-κB p65 was measured by fluorescence immunocytochemistry (200×). Red, NF-κB p65; blue, DAPI. On the 7th d of culture, (C) Measurement of ALP activity and (D) ALP staining showing that ALP was decreased after treatment with FK866. (F) Western blot results showing the protein expression of Nampt, Sirt1, TAK1, p-NF-κB p65, Runx2, Col1a1 and OCN. The data are expressed as the mean ± SD. *, ppp

Figure 5. FK866, a Nampt inhibitor, inhibited IL-6 induced inflammation and osteogenic differentiation. After treatment with 1 nM FK866 and 100 ng/mL LPS for 3 days, (A) NAD+/NADH analysis showing intracellular content of NAD+ and NADH, and their ratio. (B) ELISA result showing the IL-6 levels. (E) The nuclear translocation of NF-κB p65 was measured by fluorescence immunocytochemistry (200×). Red, NF-κB p65; blue, DAPI. On the 7th d of culture, (C) Measurement of ALP activity and (D) ALP staining showing that ALP was decreased after treatment with FK866. (F) Western blot results showing the protein expression of Nampt, Sirt1, TAK1, p-NF-κB p65, Runx2, Col1a1 and OCN. The data are expressed as the mean ± SD. *, p<0.05; **, p<0.01. #, p<0.05 vs. con.